Investigation of efficacy of levocarnitine intravenous formulation in patients undergoing hemodialysis

Investigation of efficacy of levocarnitine intravenous formulation in patients undergoing hemodialysis - Levocarnitine study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035143

Enrollment

150

Registered

2018-12-10

Start date

2018-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients with cardiac dysfunction

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hemodialysis patients with cardiac dysfunction

Exclusion criteria

Exclusion criteria: doctor's judgement, patient who did not agree with the investigation

Design outcomes

Primary

Measure	Time frame
Evaluation of cardiac function by echocardiography, before, 3, 6, 12 months after administration. Evaluation item: LVMI, LVEF, LVFS, E/A, e', E/e', LAVI	—

Secondary

Measure	Time frame
Carnitine concentration in blood symptoms side effect	—

Countries

Japan

Contacts

Public ContactShinya Minatoguchi

Gifu University Department of Circulatory and Respiratory Advanced Medicine, Graduate School of Medicine

minatos@gifu-u.ac.jp058-230-6523

Outcome results